EZH2 and melanoma: TP-472 (targeting BRD7/9), GSK-J4 (targeting KDM6A/B), GSK343 (targeting EZH2), UNC1999 (targeting EZH2/1), NVS-CERCR-1 (targeting CECR2), OF1 (targeting BRPF1/2/3; BRPF1B), and UNCO642 (targeting EHMT2) effectively inhibited the growth of both the BRAF mutant melanoma cell lines at 5 and 10 μM concentrations (Figure 1C–I).